107. Juvenile idiopathic arthritis Clinical trials / Disease details


Clinical trials : 441 Drugs : 282 - (DrugBank : 56) / Drug target genes : 52 - Drug target pathways : 142

  
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2018-001931-27-IT
(EUCTR)
28/02/201911/10/2018Comparison of therapeutic strategies in childhood ARthritiSComparison of STep-up and step-down therapeutic strategies in childhood ARthritiS - the STARS trial Juvenile idiopathic arthritis (JIA) is an umbrella term that encompasses a heterogeneous group of disorders characterised by prolonged synovial inflammation that may cause destructive damage to joint structures. Permanent changes may also develop in extraarticular organs, particularly the eye (as a complication of chronic anterior uveitis), or may result from side effects of medications.
MedDRA version: 20.0;Level: LLT;Classification code 10059177;Term: Juvenile arthritis;System Organ Class: 100000004859;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Trade Name: Reumaflex
INN or Proposed INN: METHOTREXATE
Other descriptive name: METHOTREXATE
Trade Name: Enbrel
INN or Proposed INN: ETANERCEPT
IRCCS Istituto Giannina GasliniNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
260Phase 3Italy